Adverse outcomes not improved in novel screen-and-treat program for malaria in pregnancy

A novel strategy to screen pregnant women for malaria with rapid diagnostic tests and treat the test-positive women with effective antimalarials does not lower the risk of adverse pregnancy outcomes compared with treating all pregnant women with the malaria preventive sulfadoxine-pyrimethamine (SP) in sub-Saharan Africa, according to an open label randomized trial published this week in PLOS Medicine by Feiko ter Kuile, of the Liverpool School of Tropical Medicine, and colleagues.

During pregnancy, undetected infection with malaria parasites can lead to maternal anemia, low birthweight, and fetal loss. In areas where malaria is endemic, the World Health Organization recommends treating pregnant women with SP, but in some areas, more than 90 percent of Plasmodium parasites are resistant to SP. In the new study, the researchers compared this standard of care to a screening approach where pregnant women are tested approximately monthly for malaria using rapid diagnostic tests and treated with a different drug, dihydroartemisinin-piperaquine (DP) only if they test positive for the parasite.

The study, which randomly assigned 1873 HIV-negative pregnant women at three sites in Malawi to receive either strategy, found that the risks of adverse birth outcomes, at 29.9 and 28.8 percent, was similar in the two groups. However, the prevalence of malaria at delivery was higher in the rapid screening and DP group, at 48.7 percent, compared to 40.8 percent in the SP group (relative risk=1.19 [95% confidence interval 1.07-1.33], p=0.007), meaning an additional 8 out of every 100 pregnancies would be affected by malaria using this approach compared to broad prevention using SP. Moreover, the rate of fetal loss was 2.6 percent, double the rate of 1.3 percent seen among women who took intermittent doses of SP (relative risk=2.06 [1.01-4.21], p=0.046). The current results, however, may not hold true in all areas because risk of malaria transmission varies according to location, as does parasite resistance to drugs. In addition, the study design did not investigate the outcomes of using monthly DP for prevention without coupling it to screening.

"These results suggest that [intermittent screening and treatment with DP] may not be a suitable alternative strategy to replace [intermittent preventive therapy with SP] in settings similar to ours and may even predispose to unfavorable pregnancy outcomes in these settings," the authors say.


In your coverage please use this URL to provide access to the freely available paper:


This study was funded by a grant from the European & Developing Countries Clinical Trials Partnership (Award Number IP.2007.31080.003 to FOtK) (, supplemented by funds from the Malaria in Pregnancy Consortium, which is funded through a grant by the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine (Award Number 46099 to FOtK) ( FOtK and CK thank the US Centers for Disease Control and Prevention for salary support through a cooperative agreement between the Division of Parasitic Diseases and Malaria (Centers for Disease Control and Prevention, USA) and the Malaria Epidemiology Unit of the Liverpool School of Tropical Medicine (LSTM) held by FOtK (Award Number U01CK000146) ( SMT is supported by the National Institute of Allergy and Infectious Diseases (Award Number K08AI100924) ( Parasite genotyping was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (Award Number UL1TR001117) ( The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests:

The authors have declared that no competing interests exist.


Madanitsa M, Kalilani L, Mwapasa V, van Eijk AM, Khairallah C, Ali D, et al. (2016) Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial. PLoS Med 13(9): e1002124. doi:10.1371/journal.pmed.1002124

Author Affiliations:

College of Medicine, University of Malawi, Blantyre, Malawi,
Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom,
National Malaria Control Programme, Ministry of Health, Lilongwe, Malawi,
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America,
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, United States of America,
Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America,
Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America

Media Contact

Feiko O. ter Kuile
[email protected]

%d bloggers like this: